Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

Goldstein, 1978, Familial hypercholesterolemia: pathogenesis of a receptor disease, Johns Hopkins Med J, 143, 8

Innerarity, 1987, Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding, Proc Natl Acad Sci USA, 84, 6919, 10.1073/pnas.84.19.6919

Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat Genet, 34, 154, 10.1038/ng1161

Abifadel, 2010, Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents, Expert Opin Ther Pat, 20, 1547, 10.1517/13543776.2010.518615

Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc Natl Acad Sci USA, 100, 928, 10.1073/pnas.0335507100

Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J Biol Chem, 279, 48865, 10.1074/jbc.M409699200

McNutt, 2007, Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells, J Biol Chem, 282, 20799, 10.1074/jbc.C700095200

Benjannet, 2006, The proprotein convertase (PC) PCSK9 is inactivated by Furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications, J Biol Chem, 281, 30561, 10.1074/jbc.M606495200

Essalmani, 2011, In vivo evidence that furin from hepatocytes inactivates PCSK9, J Biol Chem, 286, 4257, 10.1074/jbc.M110.192104

Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J Clin Invest, 116, 2995, 10.1172/JCI29383

Cameron, 2006, Effect of mutations in the PCSK9 gene on the cell surface LDL receptors, Hum Mol Genet, 15, 1551, 10.1093/hmg/ddl077

Poirier, 2009, Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route, J Biol Chem, 284, 28856, 10.1074/jbc.M109.037085

Abifadel, 2009, Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease, Hum Mut, 30, 520, 10.1002/humu.20882

Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N Engl J Med, 354, 1264, 10.1056/NEJMoa054013

Brown, 2006, Biomedicine. Lowering LDL–not only how low, but how long?, Science, 311, 1721, 10.1126/science.1125884

Siest, 1998, Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas cohort, Clin Chem Lab Med, 36, 35, 10.1515/CCLM.1998.007

Dubuc, 2010, A new method for measurement of total plasma PCSK9: clinical applications, J Lipid Res, 51, 140, 10.1194/jlr.M900273-JLR200

Catalano, 2009, Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway, Arterioscler Thromb Vasc Biol, 29, 268, 10.1161/ATVBAHA.108.179416

Wang, 2004, ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins, Proc Natl Acad Sci USA, 101, 9774, 10.1073/pnas.0403506101

Catalano, 2010, Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events, J Biol Chem, 285, 40965, 10.1074/jbc.M110.154815

Beisswanger, 1998, Existence of distinct tyrosylprotein sulfotransferase genes: molecular characterization of tyrosylprotein sulfotransferase-2, Proc Natl Acad Sci USA, 95, 11134, 10.1073/pnas.95.19.11134

Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat Struct Mol Biol, 14, 413, 10.1038/nsmb1235

Miyake, 2008, Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population, Atherosclerosis, 196, 29, 10.1016/j.atherosclerosis.2006.12.035

Surdo, 2011, Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH, EMBO Rep, 12, 1300, 10.1038/embor.2011.205

De Grooth, 2004, The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia, Atherosclerosis, 173, 261, 10.1016/j.atherosclerosis.2003.11.020